Praxis Precision price target lowered to $85 from $150 at Needham
Needham lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $150 and keeps a Buy rating on the shares. The firm is removing Ulixa sales from its model after the company disclosed ...
Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide
Financially stable with $469.5 million in cash, Praxis Precision Medicines can fund operations until 2028. Read why my rating on PRAX stock remains as a "Hold".
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
Praxis' epilepsy pipeline takes center stage after Ulixacaltamide's Phase 3 futility. Key trials for vormatrigine and ...
Hosted on MSN22h
Praxis Precision continues with ET trial despite likely failure warning
US-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an ...
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate
Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.
Praxis Precision price target lowered to $85 from $175 at Truist
Truist analyst Joon Lee lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $175 and keeps a Buy rating on the shares.
Praxis Precision Medicines Shares Slide on Study Setback
Praxis Precision Medicines shares lost more than a third of their value on Friday after the clinical-stage biopharmaceutical company suffered a setback in its late-stage studies of its ulixacaltamide ...
Praxis shares slump as committee says drug trial unlikely to meet main goal
Praxis Precision Medicines said an independent committee had recommended stopping a late-stage trial of an experimental drug for a movement disorder as it was unlikely to meet the main goal, sending ...
Praxis' tremor drug trial unlikely to meet main goal
Praxis Precision Medicines said on Friday an independent committee had recommended that its tremor drug trial be stopped for futility, as the trial was unlikely to meet the main goal. Shares of the ...
Praxis Precision: Panel Recommends Stopping Essential Tremor Study for Futility
Praxis on Friday said the independent data monitoring committee overseeing an interim analysis of Study 1 of the "Essential3" program has recommended that the study be stopped for futility because it ...
Praxis Precision says IDMC recommends Essential3 study be stopped for futility
The Independent Data Monitoring Committee overseeing the interim analysis of Study 1 of the Essential3 program has provided Praxis with the ...
BioWorld4d
DMC’s phase III tremor finding shakes Praxis theory
After Study 1’s independent data monitoring committee said the experiment will likely fall short of its primary endpoint with ulixacaltamide in essential tremor, Praxis Precision Medicines Inc. plans ...